Pulmonary hypertension and chronic lung disease: where are we headed?
Davide EliaAntonella CaminatiMaurizio ZompatoriRoberto CassandroChiara LonatiFrancesca LuisiGiuseppe PelosiSteeve ProvencherSergio Alfonso HarariPublished in: European respiratory review : an official journal of the European Respiratory Society (2019)
Pulmonary hypertension related to chronic lung disease, mainly represented by COPD and idiopathic pulmonary fibrosis, is associated with a worse outcome when compared with patients only affected by parenchymal lung disease. At present, no therapies are available to reverse or slow down the pathological process of this condition and most of the clinical trials conducted to date have had no clinically significant impact. Nevertheless, the importance of chronic lung diseases is always more widely recognised and, along with its increasing incidence, associated pulmonary hypertension is also expected to be growing in frequency and as a health burden worldwide. Therefore, it is desirable to develop useful and reliable tools to obtain an early diagnosis and to monitor and follow-up this condition, while new insights in the therapeutic approach are explored.
Keyphrases
- pulmonary hypertension
- idiopathic pulmonary fibrosis
- pulmonary artery
- clinical trial
- pulmonary arterial hypertension
- healthcare
- end stage renal disease
- public health
- chronic obstructive pulmonary disease
- newly diagnosed
- ejection fraction
- risk factors
- mental health
- interstitial lung disease
- drug induced
- randomized controlled trial
- risk assessment
- health information
- peritoneal dialysis
- climate change
- cystic fibrosis
- systemic sclerosis
- social media